Literature DB >> 23052417

Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155).

Hugues Chevassus1, Anne Farret, Jean-Pierre Gagnol, Claire-Anne Ponçon, Françoise Costa, Clarisse Roux, Florence Galtier, Pierre Petit.   

Abstract

PURPOSE: Bupropion is largely used as an antidepressant and smoking cessation therapy. The aim of this work was to compare pharmacodynamic properties of bupropion and the amphetamine-like methylphenidate after sustained administration in humans.
METHODS: Twelve male volunteers completed this randomized, double-blind, placebo controlled, cross-over study. Bupropion and methylphenidate were administered separately for initial half-dose 6-day periods (150 and 10 mg respectively) followed by full-dose 8-day periods (300 and 20 mg respectively). Outcomes were subjective feelings, cognitive performances, autonomic and physiological parameters.
RESULTS: Data are expressed as mean(SEM). After repeated administration, bupropion, like methylphenidate, decreased asthenia-fatigue [44(3.2) and 42(3.7), respectively vs. 53(4.1) for placebo; p = 0.034], despite an impairment of sleep onset [-4.3(3.32) and -1.9(3.76), respectively vs. +7.5(3.69); p = 0.016]. Both drugs increased resting diastolic blood pressure [67.9(1.23) and 65.7(0.98), respectively vs. 62.5(1.42) mm Hg; p = 0.001], body temperature [36.5(0.12) and 36.5(0.14) vs. 36.3(0.10) °C; p = 0.037] and decreased body weight [-0.7(0.23) and -0.6(0.22), respectively vs. +0.2(0.27) kg; p = 0.038]. No significant change could be observed on cognitive functions, appetite and energy consumption.
CONCLUSION: Although it may not share all the properties of stimulant drugs, the effect profile of bupropion presents a number of similarities with that of methylphenidate over a 2-week treatment period.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052417     DOI: 10.1007/s00228-012-1418-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  Antidepressants for smoking cessation.

Authors:  J R Hughes; L F Stead; T Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man.

Authors:  André F Carvalho; Cristiano A Köhler; Eduardo P Cruz; Pablo L Stürmer; Bruno P Reichman; Bianca M Barea; Iván Izquierdo; Márcia L F Chaves
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-05-10       Impact factor: 5.270

4.  The action of sedatives on brain stem oculomotor systems in man.

Authors:  H Norris
Journal:  Neuropharmacology       Date:  1971-03       Impact factor: 5.250

Review 5.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

6.  Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats.

Authors:  P Munzar; S R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

7.  Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.

Authors:  Thomas F Newton; John D Roache; Richard De La Garza; Timothy Fong; Christopher L Wallace; Shou-Hua Li; Ahmed Elkashef; Nora Chiang; Roberta Kahn
Journal:  Neuropsychopharmacology       Date:  2005-11-23       Impact factor: 7.853

8.  Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Authors:  Timothy E Wilens; Paul G Hammerness; Joseph Biederman; Anne Kwon; Thomas J Spencer; Sarah Clark; Megan Scott; Amy Podolski; Jeffrey W Ditterline; Matthew C Morris; Hadley Moore
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

9.  A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car.

Authors:  Fran Ridout; Ziba Shamsi; Robert Meadows; Sigurd Johnson; Ian Hindmarch
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

10.  Neurochemical and psychotropic effects of bupropion in healthy male subjects.

Authors:  Gabriella Gobbi; Susan Slater; Nathalie Boucher; Guy Debonnel; Pierre Blier
Journal:  J Clin Psychopharmacol       Date:  2003-06       Impact factor: 3.153

View more
  4 in total

1.  [Intravenous abuse of bupropione].

Authors:  N Behler; A Lehmann; B Malchow; U Palm
Journal:  Nervenarzt       Date:  2017-11       Impact factor: 1.214

2.  Bupropion increases activation in nucleus accumbens during anticipation of monetary reward.

Authors:  Yumiko Ikeda; Takuya Funayama; Amane Tateno; Haruhisa Fukayama; Yoshiro Okubo; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2019-07-24       Impact factor: 4.530

Review 3.  Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.

Authors:  Sarah Dahlberg; Ellen T Chang; Sheila R Weiss; Pamela Dopart; Errol Gould; Mary E Ritchey
Journal:  Diabetes Metab Syndr Obes       Date:  2022-09-29       Impact factor: 3.249

4.  Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and MetaForest.

Authors:  Xavier Castells; Marc Saez; Maghie Barcheni; Ruth Cunill; Domènec Serrano; Beatriz López; Caspar J van Lissa
Journal:  Int J Neuropsychopharmacol       Date:  2022-01-12       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.